MX2018009413A - Composiciones que contienen tucaresol o sus analogos. - Google Patents
Composiciones que contienen tucaresol o sus analogos.Info
- Publication number
- MX2018009413A MX2018009413A MX2018009413A MX2018009413A MX2018009413A MX 2018009413 A MX2018009413 A MX 2018009413A MX 2018009413 A MX2018009413 A MX 2018009413A MX 2018009413 A MX2018009413 A MX 2018009413A MX 2018009413 A MX2018009413 A MX 2018009413A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- formula
- tucaresol
- analogs
- compositions containing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 title 1
- 229950009795 tucaresol Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 230000006044 T cell activation Effects 0.000 abstract 1
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 abstract 1
- 229950011498 plinabulin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describen en la presente composiciones que incluyen un compuesto de la formula (I) para tratar cáncer. Algunas modalidades se refieren a métodos para tratar cáncer por co-administración de un compuesto de la formula (I) y un inhibidores de puntos de control inmunitarios a un sujeto en necesidad de los mismos. Algunas modalidades se refieren a métodos para tratar cáncer por co-administración de un compuesto de la fórmula (I) y plinabulina a un sujeto en necesidad de los mismos. Algunas modalidades se refieren a la provisión de co-estimulación de activación de células T contra cáncer por co-administración de un compuesto de la formula (I), uno o más inhibidores de puntos de control inmunitarios.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662292763P | 2016-02-08 | 2016-02-08 | |
PCT/US2017/016740 WO2017139231A1 (en) | 2016-02-08 | 2017-02-06 | Compositions containing tucaresol or its analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018009413A true MX2018009413A (es) | 2019-05-15 |
Family
ID=59563990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009413A MX2018009413A (es) | 2016-02-08 | 2017-02-06 | Composiciones que contienen tucaresol o sus analogos. |
Country Status (18)
Country | Link |
---|---|
US (2) | US10912748B2 (es) |
EP (1) | EP3413885A4 (es) |
JP (2) | JP2019511565A (es) |
KR (1) | KR20180105685A (es) |
CN (1) | CN108778267A (es) |
AU (1) | AU2017217426B2 (es) |
BR (1) | BR112018016054A2 (es) |
CA (1) | CA3013467A1 (es) |
CO (1) | CO2018009096A2 (es) |
EC (1) | ECSP18067631A (es) |
IL (1) | IL260933B2 (es) |
MX (1) | MX2018009413A (es) |
MY (1) | MY192703A (es) |
NZ (1) | NZ744854A (es) |
PH (1) | PH12018501669A1 (es) |
RU (1) | RU2753543C1 (es) |
SG (1) | SG11201806583XA (es) |
WO (1) | WO2017139231A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017011374A (es) | 2015-03-06 | 2018-01-23 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
AU2016229295B2 (en) | 2015-03-06 | 2021-11-04 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
KR20180027563A (ko) | 2015-07-13 | 2018-03-14 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린 조성물 |
US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
KR20190015361A (ko) | 2016-06-06 | 2019-02-13 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증을 줄이는 조성물 및 방법 |
JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
JP2020514412A (ja) | 2017-02-01 | 2020-05-21 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | 好中球減少症の低減方法 |
ES2942889T3 (es) * | 2017-03-13 | 2023-06-07 | Beyondspring Pharmaceuticals Inc | Composiciones de plinabulina y uso de las mismas |
CN109420167B (zh) * | 2017-08-28 | 2022-02-11 | 四川九章生物科技有限公司 | 一种***的联合用药物 |
CN112135614A (zh) | 2018-01-24 | 2020-12-25 | 大连万春布林医药有限公司 | 通过施用普那布林减少血小板减少症的组合物和方法 |
CA3133175A1 (en) * | 2019-03-14 | 2020-09-17 | Engene, Inc. | Reversible coating of chitosan-nucleic acid nanoparticles and methods of their use |
KR20220054853A (ko) * | 2019-09-03 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치료 방법 |
CN112778155B (zh) * | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | 妥卡雷琐衍生物及其用途 |
BR112022022401A2 (pt) * | 2020-05-04 | 2022-12-13 | Beyondspring Pharmaceuticals Inc | Terapia de combinação tripla para aumentar o extermínio de células cancerígenas em cânceres com baixa imunogenicidade |
Family Cites Families (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MW2380A1 (en) * | 1979-06-29 | 1982-03-10 | Wellcome Found | Pharmaceutical ethers,preparation,use and intermediates therefor and their preparation |
DK160866C (da) | 1980-12-18 | 1991-10-14 | Wellcome Found | Analogifremgangsmaade til fremstilling af phenoletherforbindelser |
AU576322B2 (en) | 1983-07-22 | 1988-08-25 | Ici Australia Limited | Alpha-substituted-alpha-cyanomethyl alcohols |
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
JPH05255106A (ja) | 1990-10-31 | 1993-10-05 | Toray Ind Inc | 血小板減少症治療剤 |
JPH059164A (ja) | 1991-07-02 | 1993-01-19 | Sumitomo Chem Co Ltd | 光学活性マンデロニトリル誘導体の製造方法 |
GB9217331D0 (en) | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
US6096786A (en) * | 1992-10-01 | 2000-08-01 | Glaxo Wellcome Inc. | Immunopotentiatory agent and physiologically acceptable salts thereof |
SG48993A1 (en) * | 1992-10-01 | 1998-05-18 | Wellcome Found | Immunopotentiatory agent and physiologically acceptable salts thereof |
US5872151A (en) | 1992-10-01 | 1999-02-16 | Glaxo Wellcome Inc. | Immunopotentiatory agents and physiologically acceptable salts thereof |
WO1994012031A1 (en) | 1992-11-27 | 1994-06-09 | Napro Biotherapeutics, Inc. | Injectable composition |
JPH0725858A (ja) | 1993-07-13 | 1995-01-27 | Otsuka Pharmaceut Co Ltd | ピペラジン誘導体 |
US5958980A (en) * | 1993-08-26 | 1999-09-28 | Glaxo Wellcome, Inc. | Immunopotentiatory agent and physiologically acceptable salts thereof |
IL110787A0 (en) | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
GB9402809D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
GB9402807D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
GB9426224D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
US5891877A (en) | 1995-02-14 | 1999-04-06 | Xenova Limited | Pharmaceutical compounds |
US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
JP3131574B2 (ja) | 1996-09-04 | 2001-02-05 | 新日本製鐵株式会社 | 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤 |
US5939098A (en) | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
US6479484B1 (en) | 1997-11-21 | 2002-11-12 | Euro-Celtique S.A. | Substituted 2-aminoacetamides and the use thereof |
KR20010034469A (ko) | 1998-01-29 | 2001-04-25 | 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 | N-[(지방족 또는 방향족)카보닐]-2-아미노아세트아미드화합물 및 환화 화합물의 제조방법 |
US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
US6069146A (en) | 1998-03-25 | 2000-05-30 | The Regents Of The University Of California | Halimide, a cytotoxic marine natural product, and derivatives thereof |
PL343249A1 (en) | 1998-03-26 | 2001-07-30 | Shionogi & Co | Indole derivatives with antiviral activity |
US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
GB9818627D0 (en) | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US7026322B2 (en) | 1998-11-12 | 2006-04-11 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
US6358957B1 (en) | 1998-11-12 | 2002-03-19 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
ATE353365T1 (de) | 1999-08-23 | 2007-02-15 | Dana Farber Cancer Inst Inc | Neue b7-4 moleküle und deren verwendungen |
JP4896327B2 (ja) | 1999-08-23 | 2012-03-14 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | Pd−1、b7−4の受容体、およびその使用 |
CA2392477A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
BR0017067A (pt) | 2000-01-18 | 2002-10-22 | Nereus Pharmaceuticals Inc | Inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto |
AU2001245823A1 (en) * | 2000-03-17 | 2001-10-03 | Corixa Corporation | Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
DE60137037D1 (de) | 2000-05-09 | 2009-01-29 | Angiorx Corp | Piperazindion-verbindungen |
EP1345938A1 (en) | 2000-12-28 | 2003-09-24 | Neurocrine Biosciences, Inc. | Tricyclic crf receptor antagonists |
US20030082140A1 (en) | 2001-08-20 | 2003-05-01 | Fisher Paul B. | Combinatorial methods for inducing cancer cell death |
AU2003213673A1 (en) | 2002-03-01 | 2003-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
KR20050000544A (ko) | 2002-05-17 | 2005-01-05 | 아방티 파르마 소시에테 아노님 | 유방암 및 난소암의 보조 요법에서도세탁셀/독소루비신/사이클로포스파미드의 용도 |
US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
US7935704B2 (en) | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
CA2494049C (en) | 2002-08-02 | 2011-10-18 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
SE0202429D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
EP1711487A1 (en) | 2004-02-04 | 2006-10-18 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
EA010198B1 (ru) | 2004-04-19 | 2008-06-30 | Крка, Товарна Здравил, Д.Д., Ново Место | Способы получения полиморфной формы i гидросульфата клопидогрела |
SI2439273T1 (sl) * | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
EP1926724A1 (en) | 2005-09-21 | 2008-06-04 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
JP2009523813A (ja) | 2006-01-18 | 2009-06-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法 |
WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
JP5755839B2 (ja) * | 2007-02-15 | 2015-07-29 | マンカインド コーポレイション | T細胞応答の増強方法 |
WO2008128169A1 (en) | 2007-04-13 | 2008-10-23 | Abraxis Bioscience, Inc. | Sparc and methods of use thereof |
US20090170837A1 (en) | 2007-08-17 | 2009-07-02 | Thallion Pharmaceuticals Inc. | Methods for treating ras driven cancer in a subject |
US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
EP2227296B1 (en) | 2008-01-08 | 2015-11-25 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
UA109108C2 (uk) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитіло до pd-l1 та його застосування для посилення функції t-клітин |
EA023344B1 (ru) | 2009-01-16 | 2016-05-31 | Тева Фармасьютикал Индастриз Лтд. | Способ лечения или предотвращения нейтропении или лейкопении или снижения частоты возникновения инфекции, проявляющейся фебрильной нейтропенией |
WO2010114922A1 (en) | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
CA2770397A1 (en) | 2009-08-10 | 2011-02-17 | Board Of Regents, The University Of Texas System | Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors |
US20110160159A1 (en) | 2009-09-15 | 2011-06-30 | John Ryan | Treatment of cancer |
CA2778707A1 (en) | 2009-10-23 | 2011-04-28 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
CN101766815B (zh) | 2009-12-31 | 2012-04-25 | 胡松华 | 紫杉醇及多西紫杉醇的用途 |
US20130225424A1 (en) | 2010-03-03 | 2013-08-29 | Targeted Molecular Diagnostics, Llc | Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification |
US20130064831A1 (en) | 2010-05-17 | 2013-03-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
US20130131018A1 (en) | 2010-06-04 | 2013-05-23 | Exonhit S.A. | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
JP2012033526A (ja) | 2010-07-28 | 2012-02-16 | Fuji Electric Co Ltd | 薄膜太陽電池およびその製造方法 |
WO2012035436A1 (en) * | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
WO2012074904A2 (en) | 2010-11-29 | 2012-06-07 | Precision Therapeutics, Inc. | Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents |
TWI386203B (zh) | 2011-01-07 | 2013-02-21 | Univ China Medical | 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用 |
DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
JP2014533955A (ja) | 2011-11-28 | 2014-12-18 | ナショナル リサーチ カウンシル オブ カナダ | パクリタキセル応答性がんマーカー |
US20150004175A1 (en) | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
CA3122808A1 (en) | 2012-05-09 | 2013-11-14 | Cantex Pharmaceuticals, Inc. | Treatment of myelosuppression |
AU2013204313C1 (en) | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
US10034939B2 (en) | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
DK2958943T3 (da) | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
WO2014160183A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
EP2988668B1 (en) | 2013-04-24 | 2019-07-24 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Magnetic resonance maps for analyzing tissue |
JP2016520643A (ja) | 2013-06-03 | 2016-07-14 | ノバルティス アーゲー | 抗pd−l1抗体とmek阻害薬および/またはbraf阻害薬の組み合わせ物 |
CN105705148B (zh) | 2013-10-11 | 2021-03-23 | 大连万春布林医药有限公司 | 使用普那布林和紫杉烷的组合的癌症疗法 |
JP2016540042A (ja) * | 2013-11-05 | 2016-12-22 | コグネート バイオサービシズ, インコーポレイテッド | がんを処置するためのチェックポイント阻害剤および治療薬の組合せ |
JP6657105B2 (ja) | 2013-11-06 | 2020-03-04 | アメリカ合衆国 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
CN104796448B (zh) | 2014-01-22 | 2019-02-12 | 腾讯科技(深圳)有限公司 | 网络***的数据处理方法和装置 |
US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
JP6698084B2 (ja) * | 2014-08-08 | 2020-05-27 | オンコクエスト インコーポレイテッドOncoquest Inc. | がんのチェックポイント干渉療法の成績を高めるための腫瘍抗原特異的抗体およびtlr3刺激 |
WO2016081281A1 (en) | 2014-11-17 | 2016-05-26 | Salk Institute For Biological Studies | Lipophilic bisphosphonates and methods of use |
MX2017010338A (es) | 2015-02-12 | 2017-12-20 | Beyondspring Pharmaceuticals Inc | Uso de plinabulina en combinación con inhibidores de punto de control inmunitario. |
AU2016229295B2 (en) | 2015-03-06 | 2021-11-04 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
MX2017011374A (es) | 2015-03-06 | 2018-01-23 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
WO2016165007A1 (en) | 2015-04-17 | 2016-10-20 | The University Of British Columbia | Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer |
CN106279039B (zh) | 2015-06-02 | 2019-01-11 | 青岛海洋生物医药研究院股份有限公司 | 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用 |
KR20180027563A (ko) | 2015-07-13 | 2018-03-14 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린 조성물 |
WO2017062505A1 (en) | 2015-10-05 | 2017-04-13 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
US10912748B2 (en) * | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
KR20190015361A (ko) | 2016-06-06 | 2019-02-13 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증을 줄이는 조성물 및 방법 |
JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
JP2020514412A (ja) | 2017-02-01 | 2020-05-21 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | 好中球減少症の低減方法 |
ES2942889T3 (es) | 2017-03-13 | 2023-06-07 | Beyondspring Pharmaceuticals Inc | Composiciones de plinabulina y uso de las mismas |
US10933061B2 (en) | 2017-12-21 | 2021-03-02 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate therapies and methods of use |
CN112135614A (zh) | 2018-01-24 | 2020-12-25 | 大连万春布林医药有限公司 | 通过施用普那布林减少血小板减少症的组合物和方法 |
NZ766454A (en) | 2018-02-01 | 2024-02-23 | Beyondspring Pharmaceuticals Inc | Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent |
CN110240592A (zh) | 2018-03-08 | 2019-09-17 | 青岛海洋生物医药研究院股份有限公司 | (z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用 |
CN111936143A (zh) | 2018-04-05 | 2020-11-13 | 诺维嘉研究公司 | 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品 |
CN112543636B (zh) | 2018-06-01 | 2024-03-01 | 大连万春布林医药有限公司 | 治疗与egfr突变相关的癌症的组合物和方法 |
CN112638388A (zh) | 2018-08-16 | 2021-04-09 | 大连万春布林医药有限公司 | 刺激免疫反应的方法和组合物 |
WO2020102244A1 (en) | 2018-11-14 | 2020-05-22 | Beyondspring Pharmaceuticals, Inc. | Methods of treating cancer using tubulin binding agents |
CN112778155B (zh) | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | 妥卡雷琐衍生物及其用途 |
BR112022022401A2 (pt) | 2020-05-04 | 2022-12-13 | Beyondspring Pharmaceuticals Inc | Terapia de combinação tripla para aumentar o extermínio de células cancerígenas em cânceres com baixa imunogenicidade |
-
2017
- 2017-02-06 US US16/075,942 patent/US10912748B2/en active Active
- 2017-02-06 MX MX2018009413A patent/MX2018009413A/es unknown
- 2017-02-06 AU AU2017217426A patent/AU2017217426B2/en active Active
- 2017-02-06 CN CN201780018762.6A patent/CN108778267A/zh active Pending
- 2017-02-06 SG SG11201806583XA patent/SG11201806583XA/en unknown
- 2017-02-06 KR KR1020187024294A patent/KR20180105685A/ko active Search and Examination
- 2017-02-06 JP JP2018560724A patent/JP2019511565A/ja active Pending
- 2017-02-06 IL IL260933A patent/IL260933B2/en unknown
- 2017-02-06 MY MYPI2018702720A patent/MY192703A/en unknown
- 2017-02-06 WO PCT/US2017/016740 patent/WO2017139231A1/en active Application Filing
- 2017-02-06 NZ NZ744854A patent/NZ744854A/en unknown
- 2017-02-06 CA CA3013467A patent/CA3013467A1/en active Pending
- 2017-02-06 RU RU2018128290A patent/RU2753543C1/ru active
- 2017-02-06 EP EP17750611.0A patent/EP3413885A4/en active Pending
- 2017-02-06 BR BR112018016054-7A patent/BR112018016054A2/pt not_active Application Discontinuation
-
2018
- 2018-08-06 PH PH12018501669A patent/PH12018501669A1/en unknown
- 2018-08-29 CO CONC2018/0009096A patent/CO2018009096A2/es unknown
- 2018-09-07 EC ECSENADI201867631A patent/ECSP18067631A/es unknown
-
2021
- 2021-02-08 US US17/170,058 patent/US11857522B2/en active Active
-
2022
- 2022-04-07 JP JP2022063979A patent/JP2022088662A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ECSP18067631A (es) | 2018-09-30 |
EP3413885A4 (en) | 2019-09-18 |
SG11201806583XA (en) | 2018-09-27 |
EP3413885A1 (en) | 2018-12-19 |
AU2017217426B2 (en) | 2022-12-01 |
BR112018016054A2 (pt) | 2019-02-12 |
IL260933A (en) | 2018-10-31 |
JP2022088662A (ja) | 2022-06-14 |
RU2753543C1 (ru) | 2021-08-17 |
US11857522B2 (en) | 2024-01-02 |
NZ744854A (en) | 2020-01-31 |
US10912748B2 (en) | 2021-02-09 |
WO2017139231A1 (en) | 2017-08-17 |
PH12018501669A1 (en) | 2019-06-17 |
US20210161844A1 (en) | 2021-06-03 |
AU2017217426A1 (en) | 2018-08-23 |
JP2019511565A (ja) | 2019-04-25 |
US20190380983A1 (en) | 2019-12-19 |
CO2018009096A2 (es) | 2019-04-30 |
KR20180105685A (ko) | 2018-09-28 |
IL260933B (en) | 2022-12-01 |
MY192703A (en) | 2022-09-02 |
IL260933B2 (en) | 2023-04-01 |
CN108778267A (zh) | 2018-11-09 |
CA3013467A1 (en) | 2017-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501669A1 (en) | Compositions containing tucaresol or its analogs | |
MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
MX2019011431A (es) | Inhibidores de proteina 1 de muerte celular programada (pd-1)/ligando 1 de muerte programada (pd-l1). | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
PH12017501413A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
NZ742742A (en) | Compositions and methods for inhibiting arginase activity | |
CL2019000844A1 (es) | Compuesto de piridina. | |
CL2016003350A1 (es) | Inhibidores de demetilasa-1 especifica de lisina | |
MX2018002049A (es) | Diacereina o sus analogos para inhibir la expresion de proteina como mota relacionada a la apoptosis que contiene un dominio de reclutamiento de caspasa (asc), expresion de dominios de pirina y familia nlr que contienen 3 (nlrp3) y/o formacion de complejo de inflamasoma de nlrp3. | |
PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
MX2016011897A (es) | Composiciones de compuestos selenoorganicos y metodos de uso de los mismos. | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
DOP2017000111A (es) | Inhibidor de cinasa aurora a | |
PH12017501879A1 (en) | Methods for treating cancer | |
MY183327A (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
MX2017012068A (es) | Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos. | |
MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
NZ757526A (en) | Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction | |
AR109328A1 (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
MX2020005454A (es) | Tratamiento de cancer mejorado. | |
IN2013DE03665A (es) |